Roux-en-Y胃旁路术与袖状胃切除术后的新发心血管事件风险:基于理赔数据的回顾性队列研究
该回顾性队列研究利用保险理赔数据,比较2010至2021年间接受Roux-en-Y胃旁路术(RYGB)与袖状胃切除术(SG)患者的心血管疾病(CVD)结局。匹配加权后共纳入13,545例SG和RYGB患者,平均随访2.5年。总体队列中两种术式的主要不良心血管事件(MACE)风险无差异(aHR 1.01,95%CI 0.90–1.12),但合并2型糖尿病(T2D)或术前已有CVD/高并发症风险的患者接受RYGB后MACE风险更低。
要点
- 总体及老年人群,RYGB与SG的MACE风险无显著差异。
- 合并T2D者,RYGB较SG的MACE风险更低(aHR 0.78,95%CI 0.66–0.92)。
- 术前已有CVD或高并发症风险者,RYGB的MACE风险更低(aHR 0.81,95%CI 0.70–0.93)。
核心结论
- 总体队列中RYGB与SG的MACE风险无差异。
- 合并T2D或术前已有CVD/高并发症风险的患者,RYGB的MACE风险低于SG。
- 研究支持对合并T2D或已有CVD的患者优先选择RYGB而非SG。
研究设计与样本
- 基于保险理赔数据的回顾性队列研究,纳入2010至2021年间接受RYGB或SG的患者。
- 匹配加权后共13,545例SG和RYGB患者,平均随访2.5年,5年末失访率26.2%。
- 采用多变量Cox比例风险模型比较累积CVD事件风险,并分析老年、T2D、已有CVD或高并发症风险亚组。
主要发现
- 总体队列MACE风险:RYGB vs SG的aHR为1.01(95%CI 0.90–1.12)。
- 老年亚组MACE风险:RYGB vs SG的aHR为0.97(95%CI 0.85–1.10)。
- T2D亚组MACE风险:RYGB vs SG的aHR为0.78(95%CI 0.66–0.92)。
- 术前已有CVD或高并发症风险亚组MACE风险:RYGB vs SG的aHR为0.81(95%CI 0.70–0.93)。
临床怎么用
- 对合并T2D的减重手术患者,可优先考虑RYGB以降低MACE风险。
- 对术前已有CVD或高并发症风险的患者,RYGB可能较SG更具心血管获益。
- 对老年患者或其他人群,RYGB与SG的MACE风险无显著差异,术式选择需综合评估。
局限性
- 回顾性理赔数据可能存在编码偏倚和未测量混杂。
- 平均随访2.5年,5年末失访率26.2%,长期结局需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of incident cardiovascular disease (CVD) events following sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). BACKGROUND: Bariatric surgery is associated with reduced CVD risk, but the differential effect of contemporary bariatric procedures is unclear. METHODS: We used insurance claims to conduct a retrospective cohort study of CVD outcomes for patients who underwent RYGB versus SG between 2010 and 2021. Patients were followed for up to 5 years for a primary composite major adverse cardiovascular event (MACE) outcome as well as individual outcomes, including myocardial infarction, stroke, heart failure, and arrhythmia. We compared cumulative risks of CVD events using multivariable Cox proportional hazards modeling in overall cohorts and subcohorts of older adults and those with type 2 diabetes (T2D) or pre-existing CVD and elevated morbidity. RESULTS: Matched, weighted cohorts of 13,545 SG and RYGB patients were observed for an average of 2.5 years after surgery, with 26.2% not lost to follow-up by the end of 5 years. There was no difference in MACE risk between procedures [adjusted hazard ratio (aHR): 1.01 for RYGB vs. SG (95% CI: 0.90, 1.12)] in the overall cohort or among the subgroup of older adults [aHR: 0.97 for RYGB vs. SG (95% CI: 0.85, 1.10)]. Patients with T2D experienced a lower risk of MACE following RYGB compared with SG [aHR: 0.78 (95% CI: 0.66, 0.92)], as did those with pre-existing CVD or elevated morbidity before surgery [aHR: 0.81 (95% CI: 0.70, 0.93)]. CONCLUSIONS: These findings further support the preferential use of RYGB over SG for patients with T2D or who have pre-existing CVD. However, among other groups of patients, including older adults, we did not observe a relative benefit of RYGB during the time horizon in this study.
引用
- Lewis KH, Argetsinger S, LeCates RF, et al. Risk of Incident Cardiovascular Events Following Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Claims-based Retrospective Cohort Study. Ann Surg. 2024. PMID: 39177643. doi:10.1097/SLA.0000000000006507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。